Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283726 | 0.79 | CYP19A1 (0.42) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL5943437 | 0.72 | ESR1 (0.50) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL11663664 | 0.69 | NFE2L2 (0.39) | CYP19A1CYP11B2ALDH1A1 | |
| SCHEMBL283727 | 0.68 | CYP19A1 (0.59) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL11694840 | 0.67 | ESR1 (0.59) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL619504 | 0.65 | SNCA (0.32) | ESR1ALDH1A1 | |
| SCHEMBL4599993 | 0.65 | CYP19A1 (0.48) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL935197 | 0.64 | ALDH1A1 (0.48) | TDP1ALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL55433 | 0.64 | ESR1 (0.74) | CYP19A1CYP11B2TDP1PTGS2ESR1 | |
| SCHEMBL4612468 | 0.64 | CYP19A1 (0.52) | CYP19A1CYP11B2TDP1PTGS2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423192-A1 | METAL COMPLEX HAVING AROMATIC LIGAND THAT CONTAINS NITROGEN ATOM | Sumitomo Chemical Company, Limited (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041203-A1 | METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041203-A1 | METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM | MICA, CD4, CLTC | CYP19A1 3916/4885CYP11B2 3231/4885TDP1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.